Proportional Change in D-dimer Level From Baseline to Day 8, or Day of Discharge if Prior to Day 8 (Phase 2b)

Proportional Change in D-dimer Level From Baseline to Day 8, or Day of Discharge if Prior to Day 8 (Phase 2b)

Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization as compared to heparin (Phase 2b and 3);Proportional change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b);Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)

Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization as compared to heparin (Phase 2b and 3);Proportional change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b);Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)

Change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b);Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization as compared to heparin (Phase 2b and 3);Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)

Change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b);Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization as compared to heparin (Phase 2b and 3);Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)

Change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b);Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization;Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)

Change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b);Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization;Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)

Number of major or non-major clinically relevant bleeding events within thirty (30) days of randomization (Phase 2b);Change in D-dimer level from Baseline to Day 8 (Phase 2b);Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)

Number of major or non-major clinically relevant bleeding events within thirty (30) days of randomization (Phase 2b);Change in D-dimer level from Baseline to Day 8 (Phase 2b);Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)